within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M03B_MuscleRelaxantsCentrallyActingAgents.M03BX08_Cyclobenzaprine;

model Cyclobenzaprine
  extends Pharmacolibrary.Drugs.ATC.M.M03BX08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M03BX08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. It is indicated for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is FDA-approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Darwish, M, &amp; Xie, F (2009). Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. <i>Drugs &amp; aging</i> 26(2) 95–101. DOI:<a href=&quot;https://doi.org/10.2165/0002512-200926020-00001&quot;>10.2165/0002512-200926020-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19220066/&quot;>https://pubmed.ncbi.nlm.nih.gov/19220066</a></p></li><li><p>Winchell, GA, et al., &amp; Korn, SH (2002). Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. <i>Journal of clinical pharmacology</i> 42(1) 61–69. DOI:<a href=&quot;https://doi.org/10.1177/0091270002042001007&quot;>10.1177/0091270002042001007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11808825/&quot;>https://pubmed.ncbi.nlm.nih.gov/11808825</a></p></li><li><p>Darwish, M, et al., &amp; Xie, F (2008). Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. <i>Clinical drug investigation</i> 28(12) 793–801. DOI:<a href=&quot;https://doi.org/10.2165/0044011-200828120-00007&quot;>10.2165/0044011-200828120-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18991473/&quot;>https://pubmed.ncbi.nlm.nih.gov/18991473</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cyclobenzaprine;
